Momelotinib Dihydrochloride

4 月 30 日，葛兰素史克（GSK）发布 2025 年 Q1 财报，全年营收 75.16 亿英镑（95.04 亿美元），同比增长 4%（按固定汇率计算，下同）。研发投入 14.62 亿英镑（18.49 亿美元），同比增长 3%。来源：GSK 官网（下同）GSK 的业务主要分为特药（Specialty Medicines）、疫苗（Vaccines）以及普药（General Medicines）三个版块，2025 年 Q1 分别贡献了 29.33 亿英镑（37.10 亿美元，+17%）、20.95 亿英镑（26.48 亿美元，-6%）、24.88 亿英镑（31.46 亿美元，稳定）的业绩收入。具体来说，特药方面，GSK 在HIV、呼吸/免疫和肿瘤疾病领域分别斩获了 17 亿英镑（+7%）、8 亿英镑（+28%）、4 亿英镑（+53%），增长迅猛，尤其是肿瘤产品，已经成为 GSK 业绩新的增长点。GSK 肿瘤板块增长主要得益于骨髓纤维化贫血患者药物 Ojjaara/Omjjara（莫洛昔尼，2023 年 9 月上市）的推出，以及 PD-1 单抗 Jemperli（Dostarlimab，2021 年 4 月上市）新适应症的拓展和市场渗透程度的增加，两款产品 2025 年 Q1 销售额分别为 1.12 亿英镑和 1.74 亿英镑，2 款产品的同比增长率均大于 100%。呼吸/免疫领域，Nucala （美泊利珠单抗）和 Benlysta（贝利尤单抗）分别为 GSK 贡献了 4.44 亿英镑（+21%）和 3.59 亿英镑（+39%）的销售额。HIV 领域，GSK 手握长效产品，市场表现不俗，销售额持续增长。其中 Cabenuva（卡替拉韦+利匹韦林）、Apretude （卡替拉韦）和 Dovato （多替拉韦+拉米夫定）分别获得了 2.94 亿英镑（+38%）、0.89 亿英镑（+63%）和 5.7 亿英镑（+19%）的收入。疫苗方面，GSK 产品销售陷入疲软期，收入 20.95 亿英镑，仅脑膜炎疫苗实现了两位数增长，被寄予厚望的 RSV 疫苗 Arexvy 遭受腰斩。Arexvy 在 2023 年 5 月首次获 FDA 批准，随后又相继在欧盟、日本获批上市。作为全球首款 RSV 疫苗，Arexvy 在上市第一年便成功斩获了 15.43 亿美元的销售额。但 2024 年，由于需求下降，该产品全球销售额下滑 51%，仅有 5.90 亿英镑的收入。2025 年 Q1 销售额达 0.78 亿英镑，同比下滑 57%。Shingrix 是一款重组带状疱疹疫苗，2024 年以 33.64 亿英镑（+1%）的收入继续稳坐全球疫苗大品种的宝座。2025 Q1 该产品的销售额为 8.67 亿英镑，同比下滑 7%。脑膜炎疫苗 Meningitis（包括 Bexsero 和 Menveo ）增长强劲，为 GSK 疫苗板块注入了新的动力，2025 年 Q1 斩获了 3.5 亿英镑的销售额，同比增长 20%。GSK 在财报中披露，预计 2025 年 FDA 将批准 5 项主要新产品：2025 年第一季度批准：Penmenvy，脑膜炎疫苗；Blujepa，用于治疗尿路感染的首创抗生素预计进一步获批的药物包括：Nucala（慢性阻塞性肺病）；Blenrep（多发性骨髓瘤）；以及 Depemokimab（严重哮喘和鼻息肉）识别微信二维码，可添加药时空小编请注明：姓名+研究方向！

GSK said its decoupling with Haleon is a key reason why it views itself as “well-positioned” in the face of potential pharma-specific tariffs. When the drugmaker went through its “ demerger ” with the consumer health business in 2022, there were “very intentional, deliberate choices to reset” its supply chain for “regional resilience” as well as “double sourcing” to allow for flexibility, CEO Emma Walmsley said. It has “mitigation options” that it could execute across its manufacturing networks once pharma levies are in place, the UK company said in a statement. “We’re watching it very carefully … we are well-prepared,” Walmsley said during GSK’s first-quarter earnings call with the media. Some drug developers and CDMOs have similarly expressed how their earlier moves — which were made even before the talk of tariffs emerged — would help them navigate sector-specific levies regardless of what these might look like. President Donald Trump’s tariffs have been a central theme during this earnings season as drugmakers disclose their exposures and strategies to varying degrees. Last week, Roche CEO Thomas Schinecker said the pharma tariffs could have a negative impact on dealmaking. But Walmsley somewhat disagreed, saying “there are some opportunities” for deals and that half of GSK’s pipeline comes from this business development approach. “We’re constantly looking at things … and we also continue to look at the opportunities out of China on BD. We’ve done several good deals ,” she said. GSK’s disappointing vaccine sales stood out in Q1. Sales for this franchise dropped 6% in the quarter due to “known headwinds,” GSK said. Shingrix struggled in the US due to “harder-to-reach unvaccinated customers” and increased channel inventory consumption. As for Arexvy, sales disappointed because of the FDA’s Advisory Committee on Immunization Practices’ constricted recommendation only for people aged 60 to 74. But Jefferies analysts said GSK’s vaccine sales of £2.1 billion were actually better than consensus expectations of £2.05 billion. Shingrix beat forecasts with £867 million in worldwide sales, although Arexvy sales are still notably low at £78 million. Walmsley added that both vaccines still have room for growth internationally. Despite these market challenges, Walmsley told the media GSK does not intend to change its R&D plans for vaccines. Overall, GSK had a positive total sales profile, pulling in £7.5 billion in Q1, up 4% at constant exchange rates. Its shares were up by as much as 4% on the London Stock Exchange on Wednesday morning. The company’s specialty medicines portfolio had a particularly solid performance at £2.9 billion — a 17% jump — beating Jefferies’ consensus estimates of £2.84 billion. “We’ve been able to strengthen the portfolio with a shift to more specialty medicines, and that creates oxygen through the gross margin,” Walmsley said. Notably, Jemperli pulled in £174 million in Q1 compared with a lower benchmark of £145 million. GSK said Jemperli’s US sales momentum is supported by the drug’s approval in all patients with primary advanced or recurrent endometrial cancer. GSK also touted its market progress with Ojjaara at £112 million, as the myelofibrosis therapy makes headway in the US and other territories. But analysts noted the drug’s sales just missed forecasts at £117 million. Nonetheless, GSK’s overall showing on Wednesday follows the optimistic tune played in February, when it set a higher bar for its 2031 sales outlook to at least $40 billion. This is a £2 billion jump from a prior target. Looking at its clinical pipeline, GSK discontinued a Phase 2 trial of an anti-IL18 antibody, codenamed GSK1070806, for atopic dermatitis due to pipeline prioritization. Endpoints News previously reported that GSK’s ViiV Healthcare stopped work on its HIV antiviral named VH3739937.